Anti-γ-GIobulin Factors in Serum and Tissue of Cancer Patients

Thunold, S.; Abeyounis, C.J.; Milgrom, Felix; Witebsky, Ernest

doi:10.1159/000230279

Cited by 12 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sa/ti-et. Saliva containing IgA antibodies to rabbit erythrocytes (15) was collected in 10 ml amounts and cleared by centrifugation at 2,000 X g for 15 min.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Receptors for Immunoglobulin Fc in Human Malignant Tissues

Tönder

Thunold

1973

Scand J Immunol

Self Cite

View full text Add to dashboard Cite

Cryostat sections of 10 malignant human tumours of various types strongly adsorbed erythrocytes sensitized with IgG antibodies Normal spleen and lymph nodes showed medium Strong and thymus weak reactions. The receptors in tissue have affinity for the Fc‐portion of Ig, and (phospho)lipids are common consituents. An antiserum to a lymphoma inhibited receptor activity of all tissues. Spleen and tumour tissue removed this inhibiting activity. Tentatively, the malignant tissue seems to carry membrane receptor(s) similar in nature to receptor(s) on B lymphocytes.

show abstract

“…Sa/ti-et. Saliva containing IgA antibodies to rabbit erythrocytes (15) was collected in 10 ml amounts and cleared by centrifugation at 2,000 X g for 15 min.…”

Section: Methodsmentioning

confidence: 99%

“…8 agglutinating units could also be employed. For tests with IgA, pooled saliva from 3 individuals was employed for sensitization of rabbit erythrocytes (15). The results obtained with the various test systems are shown in Table II.…”

Section: Haemadsorption Mediated Hy Antibodies From Other Species Andmentioning

confidence: 99%

Receptors for Immunoglobulin Fc in Human Malignant Tissues

Tönder

Thunold

1973

Scand J Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…16] and malignant tissues [3,14,15] as well as lymphocytes [4], The complement receptors in the glome ruli of normal kidney reported by several investigators [ 1, 5, 6, 111 were considered to be responsible for the deposition of im mune complexes to glomeruli that is the most characteristic feature of chronic glo merulonephritis. Similar immune deposits have also been observed in the vessels of patients with various kinds of vasculitis [2,7,13].…”

mentioning

confidence: 99%

Receptors for IgG Fc and Complement in the Mammalian Aorta

Kasukawa¹,

Okada²,

Igari³

1980

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The presence of IgG Fc receptors in the tissue sections of aorta and aortic valves of man, ox and pig was demonstrated by means of hemadsorption of human and rabbit IgG antibody sensitized erythrocytes to these sections. C3b receptors in the tissue sections of aortic valves of these three mammals were also demonstrated by using sheep erythrocytes sensitized with rabbit IgM antibody which bound murine complement. 8 of 13 systemic lupus erythematosus sera and 2 of 19 other collagen disease sera were shown to be able to inhibit the adsorption of rabbit IgG antibody sensitized erythrocytes to the human aortic sections upon preincubation of the tissues with the pathologic sera. The amount of immune complexes in the ‘inhibition-positive’ sera was significantly higher than that in the negative sera.

show abstract

“…Rheumatoid factor (RF) is detected by routine laboratory techniques in serum from <4% of healthy adults under 65 years of age (1)(2)(3)(4)(5)(6)(7)(8). About 13-20% of unselected patients with malignancies are RF seropositive (1,4,5), and RF has been eluted from neoplastic but not from adjacent normal tissues (5).…”

Section: Introductionmentioning

confidence: 99%

“…About 13-20% of unselected patients with malignancies are RF seropositive (1,4,5), and RF has been eluted from neoplastic but not from adjacent normal tissues (5). The relevance of this antibody response to tumor-host interactions is not known, nor are circumstances that cause it to occur.…”

Section: Introductionmentioning

confidence: 99%

Rheumatoid factor and tumor-host interaction.

Twomey¹,

Rossen²,

Lewis³

et al. 1976

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

In this survey for rheumatoid factor (RF) seropositivity on patients with neoplasms, an 85% rate of positive screening tests was recorded under certain circumstances. This high rate of RF seropositivity occurred after irradiation and/or chemotherapy of breast and lung cancers. Treated patients with breast cancers who had no evidence of residual tumor had an 89% rate of positive RF tests. Conversely, the incidence of RF seropositivity was low among untreated patients with similar tumors and treated patients with glioblastomas or multiple myeloma. The administration of cytotoxic drugs (e.g., azathiprene) was not itself associated with RF production even in renal allograft recipients. The data indicate that RF production occurs frequently after therapy of certain tumors and suggest that in these circumstances RF may be an expression of tumor-host interaction.Rheumatoid factor (RF) is detected by routine laboratory techniques in serum from <4% of healthy adults under 65 years of age (1-8). About 13-20% of unselected patients with malignancies are RF seropositive (1, 4, 5), and RF has been eluted from neoplastic but not from adjacent normal tissues (5). The relevance of this antibody response to tumor-host interactions is not known, nor are circumstances that cause it to occur.Most RFs are IgM antibodies to antigenic determinants in IgG. In general, IgM is a more effective activator of complement than IgG (6, 7). However, the effect of IgM-RF on complement mediated reactions is variable (8-11). For example, IgM-RF induces complement-mediated neutralization of herpes simplex virus complexed to IgG antibody (9). However, RF may inhibit complement-mediated phagocytosis (10) and lysis (11) administration of various chemotherapeutic agents intravenously in dose schedules dictated by patient weight, clinical status, and drug tolerance. These drugs included cyclophosphamide, vinblastin, methotrexate, 5-fluorouracil, thio-TEPA, and steroids. Multiple myeloma was treated with irradiation, melphalan, and, in selected cases, steroids. Glioblastomas were treated with irradiation to the head and with steroids. Most patients had received prolonged courses of therapy before their serum was tested. Nineteen patients with breast cancer had no apparent residual tumor after radical mastectomy and had received "prophylactic" irradiation and chemotherapy before they were tested. Of the patients receiving cytotoxic drugs, which were administered for immunosuppression, 11 were renal allograft recipients and 10 had multiple sclerosis. The renal allograft recipients were receiving 100-175 mg of azathioprene and up to 20 mg of prednisone daily; patients with multiple sclerosis were receiving azathioprene at 50 mg/day. Sera were tested for RF at 1:20 dilutions with glycine-saline buffer using latex particles coated with Cohns Fraction II (Hyland Laboratories). RESULTSThe results of the serologic survey for RF are listed in Table 1

show abstract

Anti-γ-GIobulin Factors in Serum and Tissue of Cancer Patients

Cited by 12 publications

References 16 publications

Receptors for Immunoglobulin Fc in Human Malignant Tissues

Receptors for Immunoglobulin Fc in Human Malignant Tissues

Receptors for IgG Fc and Complement in the Mammalian Aorta

Rheumatoid factor and tumor-host interaction.

Contact Info

Product

Resources

About